AI assistant
Sending…
RHYTHM PHARMACEUTICALS, INC. — Director's Dealing 2023
Feb 16, 2023
30849_dirs_2023-02-16_ab1a2c21-14e7-45f1-83eb-fc18bea38ec3.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2023-02-14
Reporting Person: Mazabraud Yann (EVP, Head of International)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-02-14 | Common Stock | S | 1177 | $27.03 | Disposed | 3827 | Direct |
Footnotes
F1: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.
More from RHYTHM PHARMACEUTICALS, INC.
Regulatory Filings
2026
May 5
Regulatory Filings
2026
May 5
Proxy Solicitation & Information Statement
2026
Apr 29
Regulatory Filings
2026
Apr 3
Major Shareholding Notification
2026
Mar 27
Regulatory Filings
2026
Mar 20
Director's Dealing
2026
Mar 4
Director's Dealing
2026
Mar 4
Director's Dealing
2026
Mar 3
Regulatory Filings
2026
Mar 2